Keros Therapeutics earnings were $64.4M for the trailing 12 months ending Sep 30, 2025, with N/A growth year over year. The latest KROS earnings report on Sep 30, 2025 announced Q3 2025 earnings of -$7.3M, down 76.3% from last quarter. For the last reported fiscal year 2024 ending Dec 31, 2024, KROS reported annual earnings of -$187.4M, with 22.5% growth.
What were Keros Therapeutics's earnings last quarter?
On KROS's earnings call on Invalid Date, Keros Therapeutics (NASDAQ: KROS) reported Q3 2025 earnings per share (EPS) of -$0.18, up 87.23% year over year. Total KROS earnings for the quarter were -$7.28 million. In the same quarter last year, Keros Therapeutics's earnings per share (EPS) was -$1.41.
As of the last Keros Therapeutics earnings report, Keros Therapeutics is currently profitable. Keros Therapeutics's net profit (also called net income) for the twelve months ending Sep 30, 2025 was $64.45 million, a 135.5% decrease year over year.
What was KROS's earnings growth in the past year?
As of Keros Therapeutics's earnings date in Invalid Date, Keros Therapeutics's earnings has grown year over year. KROS earnings in the past year totalled $64.45 million.
WallStreetZen does not provide financial advice and does not issue recommendations or offers to buy stock or sell any security.
Information is provided 'as-is' and solely for informational purposes and is not advice. WallStreetZen does not bear any responsibility for any losses or damage that may occur as a result of reliance on this data.